Evaluation Team Reports Monster Silk™ Production Ramp Up is Succeeding
LANSING, Mich., May 29, 2014— Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced that its production evaluation team reported that the Company’s genetically engineered spider silk, Monster Silk™, production program is thriving and is successfully accommodating a recent significant increase in the scale of production.
The Company previously reported that its pilot production program’s viable silk cocoon yield rate was at approximately 30%, in late 2013. By March, after launching the commercial production ramp up program, the yields increased to approximately 70%; more than double the output efficiency from the pilot phase. The latest report is that with the increased scale of operations in May, the high yields appear to be holding, and possibly improving even further.
The Company believes that the high yield is a result of a combination of improved production procedures and adaptability. The Company is ordering a further doubling of production in June.
“We always believed that our scientific model would translate very well into real world environments, but to actually see our silkworms perform at this level is inspiring. The technology is now outperforming the infrastructural capacities, which bodes well for future product, and production, expansion,” said Company Founder and CEO, Kim K. Thompson.
“The fact that the reported yield rates are holding, or improving, has given us the confidence to authorize a doubling of the scale of production. We anticipate this next larger production run will launch in June. We are excited and encouraged to see that our systems are holding up well as we increase the scale of Monster Silk™ production, and we are working with third parties to strengthen the infrastructure to support the increased production,” Thompson concluded.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC.